<DOC>
	<DOCNO>NCT01304797</DOCNO>
	<brief_summary>This study Phase 1 pharmacologic open-label dose-escalation trial use `` 3+3 '' design . Successive cohort three patient treat escalate dos maximum tolerate dose identify . Once maximum tolerate dose identify , Expansion Cohort enrol dose characterize safety pharmacologic endpoint . Additional arm enrol explore combination MM-302 trastuzumab trastuzumab plus cyclophosphamide patient advance HER2 positive breast cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study MM-302 Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Locally advanced/unresectable metastatic breast cancer Eighteen year age Able understand sign inform consent ( legal representative able ) Measurable disease accord RECIST v1.1 ECOG Performance Score 0 1 Adequate bone marrow , hepatic , renal cardiac function Willing abstain sexual intercourse use effective form contraception study 90 day follow last dose MM302 Patients potentially curative anticancer therapy available Active infection fever &gt; 38.5Â°C screen visit first schedule day dose Symptomatic CNS disease Known hypersensitivity component MM302 hypersensitivity reaction fully human monoclonal antibody Received recent antitumor therapy Pregnant breast feeding Patients medical psychological condition , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MM302</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Locally advanced/unresectable</keyword>
	<keyword>metastatic</keyword>
</DOC>